Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vir Biotechnology (VIR) stocks

Learn how to easily invest in Vir Biotechnology stocks.

Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology stocks (VIR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.65 – an increase of 7.89% over the previous week. Vir Biotechnology employs 444 staff and has a trailing 12-month revenue of around $2.3 billion.

How to buy stocks in Vir Biotechnology

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VIR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vir Biotechnology stock price (NASDAQ:VIR)

Use our graph to track the performance of VIR stocks over time.

Vir Biotechnology shares at a glance

Information last updated 2022-06-27.
Latest market close$26.65
52-week range$18.21 - $58.00
50-day moving average $23.19
200-day moving average $32.30
Wall St. target price$52.71
PE ratio 2.7628
Dividend yield $0 (0%)
Earnings per share (TTM) $8.99

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
3.8 / 5
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Vir Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vir Biotechnology price performance over time

Historical closes compared with the close of $26.65 from 2022-06-27

1 week (2022-06-21) 7.89%
1 month (2022-05-27) -0.19%
3 months (2022-03-28) 25.77%
6 months (2021-12-28) -32.33%
1 year (2021-06-28) -43.14%
2 years (2020-06-26) -31.37%
3 years (2019-06-24) N/A
5 years (2017-06-24) N/A

Is Vir Biotechnology under- or over-valued?

Valuing Vir Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vir Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vir Biotechnology's P/E ratio

Vir Biotechnology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Vir Biotechnology shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Vir Biotechnology's EBITDA

Vir Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.

The EBITDA is a measure of a Vir Biotechnology's overall financial performance and is widely used to measure a its profitability.

Vir Biotechnology financials

Revenue TTM $2.3 billion
Operating margin TTM 70.59%
Gross profit TTM $590.7 million
Return on assets TTM 51.02%
Return on equity TTM 91.71%
Profit margin 52.29%
Book value $15.12
Market capitalisation $3.3 billion

TTM: trailing 12 months

Vir Biotechnology share dividends

We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.

Vir Biotechnology share price volatility

Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $18.21 up to $58. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -0.5804. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.

Vir Biotechnology overview

Vir Biotechnology, Inc. , a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd. ; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site